Pathophysiological aspects of pulmonary complications of cirrhosis

Scandinavian Journal of Gastroenterology

Volumn 42, Issue 4, 2007, Pages 419-427

  Møller, Søren ^a,b   Krag, Aleksander ^a   Henriksen, Jens H ^a   Bendtsen, Flemming ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b HVIDOVRE HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIAC GLYCOSIDE; DIURETIC AGENT; ENDOTHELIN RECEPTOR ANTAGONIST; NITRATE; PROSTACYCLIN DERIVATIVE; VASODILATOR AGENT;

CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CONTRAST ECHOCARDIOGRAPHY; DIFFUSION; DISEASE COURSE; FORCED EXPIRATORY VOLUME; HEART ELECTROPHYSIOLOGY; HEART OUTPUT; HEART RATE; HEPATOPULMONARY SYNDROME; HUMAN; ISCHEMIA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; LUNG COMPLICATION; LUNG VENTILATION PERFUSION RATIO; OXYGEN THERAPY; OXYGENATION; PATHOPHYSIOLOGY; PORTAL HYPERTENSION; PORTOCAVAL SHUNT; PORTOSYSTEMIC ANASTOMOSIS; PRIORITY JOURNAL; REVIEW; TOTAL LUNG CAPACITY;

CARDIOVASCULAR DISEASES; HEPATOPULMONARY SYNDROME; HUMANS; HYPERTENSION, PORTAL; HYPERTENSION, PULMONARY; LIVER CIRRHOSIS; LUNG DISEASES; PULMONARY DIFFUSING CAPACITY;

EID: 34147102858     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.1080/00365520601151695     Document Type: Review

References (85)

1. Møller S, Henriksen JH. The systemic circulation in cirrhosis. In: Gines P, Arroyo V, Rodes J, Schrier RW, editors. Ascites and renal dysfunction in liver disease. Malden: Blackwell; 2005. pp 139-55.
2. Wiest R, Groszmann RJ. The paradox of nitric oxide in cirrhosis and portal hypertension: too much, not enough. Hepatology 2002;35:478-91.
3. Møller S, Henriksen JH. Endothelins in chronic liver disease. Scand J Clin Lab Invest 1996;56:481-90.
4. Dib N, Oberti F, Cales P. Current management of the complications of portal hypertension: variceal bleeding and ascites. Can Med Assoc J 2006;174:1433-43.
5. Møller S, Bendtsen F, Henriksen JH. Splanchnic and systemic hemodynamic derangement in decompensated cirrhosis. Can J Gastroenterol 2001;15:94-106.
6. Møller S, Henriksen JH. Neurohumoral fluid regulation in chronic liver disease. Scand J Clin Lab Invest 1998;58:361-72.
7. Bernardi M, Domenicali M. The renin-angiotensin-aldosterone system in cirrhosis. In: Ginés P, Arroyo V, Rodes J, Schrier RW, editors. Ascites and renal dysfunction in liver disease. Malden: Blackwell Publishing; 2005. pp 43-54.
8. Ma Z, Lee SS. Cirrhotic cardiomyopathy: getting to the heart of the matter. Hepatology 1996;24:451-9.
9. Rodriguez-Roisin R, Krowka MJ, Herve P, Fallon MB. Pulmonary-hepatic vascular disorders (PHD). Eur Respir J 2004;24:861-80.
10. Bernardi M, Fornale L, Dimarco C, Trevisani F, Baraldini M, Gasbarrini A, et al. Hyperdynamic circulation of advanced cirrhosis: a re-appraisal based on posture-induced changes in hemodynamics. J Hepatol 1995;22:309-18.
11. Laffi G, Lagi A, Cipriani M, Barletta G, Bernardi L, Fattorini L, et al. Impaired cardiovascular autonomic response to passive tilting in cirrhosis with ascites. Hepatology 1996;24:1063-7.
12. Iwakiri Y, Groszmann RJ. The hyperdynamic circulation of chronic liver diseases: from the patient to the molecule. Hepatology 2006;43:S121-31.
13. Schrier RW, Ecder T. Unifying hypothesis of body fluid volume regulation: implications for cardiac failure and cirrhosis. Mt Sinai J Med 2001;68:350-61.
14. Møller S, Henriksen JH. Circulatory abnormalities in cirrhosis with focus on neurohumoral aspects. Semin Nephrol 1997;17:505-19.
15. Møller S, Bendtsen F, Schifter S, Henriksen JH. Relation of calcitonin gene-related peptide to systemic vasodilatation and central hypovolaemia in cirrhosis. Scand J Gastroenterol 1996;31:928-33.
16. Batkai S, Jarai Z, Wagner JA, Goparaju SK, Varga K, Liu J, et al. Endocannabinoids acting at vascular CB1 receptors mediate the vasodilated state in advanced liver cirrhosis. Nat Med 2001;7:827-32.
17. Ros J, Claria J, To-Figueras J, Planaguma A, Cejudo-Martin P, Fernandez-Varo G, et al. Endogenous cannabinoids: a new system involved in the homeostasis of arterial pressure in experimental cirrhosis in the rat. Gastroenterology 2002;122:85-93.
18. Liu H, Song D, Lee SS. Cirrhotic cardiomyopathy. Gastroenterol Clin Biol 2002;26:842-7.
19. Møller S, Henriksen JH. Cirrhotic cardiomyopathy: a pathophysiological review of circulatory dysfunction in liver disease. Heart 2002;87:9-15.
20. Møller S, Henriksen JH. Cardiovascular dysfunction in cirrhosis. Pathophysiological evidence of a cirrhotic cardiomyopathy. Scand J Gastroenterol 2001;36:785-94.
21. Zambruni A, Trevisani F, Caraceni P, Bernardi M. Cardiac electrophysiological abnormalities in patients with cirrhosis. J Hepatol 2006;44:994-1002.
22. Torregrosa M, Aguade S, Dos L, Segura R, Gonzalez A, Evangelista A, et al. Cardiac alterations in cirrhosis: reversibility after liver transplantation. J Hepatol 2005;42:68-74.
23. Gaskari SA, Honar H, Lee SS. Therapy insight: cirrhotic cardiomyopathy. Nat Clin Pract Gastroenterol Hepatol 2006;3:329-37.
24. Myers RP, Lee SS. Cirrhotic cardiomyopathy and liver transplantation. Liver Transpl 2000;6:S44-52.
25. Lebrec D, Giuily N, Hadengue A, Vilgrain V, Moreau R, Poynard T, et al. Transjugular intrahepatic portosystemic shunts: comparison with paracentesis in patients with cirrhosis and refractory ascites. A randomized trial. J Hepatol 1996;25:135-44.
26. Cotes JE. Lung function. Assessment and application in medicine, 5th ed. Oxford: Blackwell; 1993.
27. Cotes JE, Chinn DJ, Quanjer PH, Roca J, Yernault JC. Standardization of the measurement of transfer factor (diffusing capacity). Eur Respir J 1993;6(Suppl 16):41-52.
28. Agusti AGN, Roca J, Bosch J, Rodriguez-Roisin R. The lung in patients with cirrhosis. J Hepatol 1990;10:251-7.
29. Agusti AGN, Roca J, Rodriguez-Roisin R. Mechanisms of gas exchange impairment in patients with liver cirrhosis. Clin Chest Med 1996;17:49-66.
30. Chao Y, Wang SS, Lee SD, Shiao GM, Chang HI, Chang SC. Effect of large-volume paracentesis on pulmonary function in patients with cirrhosis and tense ascites. J Hepatol 1994;20:101-5.
31. Angueira CE, Kadakia SC. Effects of large-volume paracentesis on pulmonary function in patients with tense cirrhotic ascites. Hepatology 1994;20:825-8.
32. Byrd RP, Roy TM, Simons M. Improvement in oxygenation after large volume paracentesis. South Med J 1996;89:689-92.
33. Berkowitz KA, Butensky MS, Smith RL. Pulmonary function changes after large volume paracentesis. Am J Gastroenterol 1993;88:905-7.
34. Møller S, Becker U, Schifter S, Abrahamsen J, Henriksen JH. Effect of oxygen inhalation on systemic, central, and splanchnic haemodynamics in cirrhosis. J Hepatol 1996;25:316-28.
35. Krowka MJ. Hepatopulmonary syndromes. Gut 2000;46:1-4.
36. Fallon MB, Abrams GA. Pulmonary dysfunction in chronic liver disease. Hepatology 2000;32:859-65.
37. Møller S, Hillingsø J, Christensen E, Henriksen JH. Arterial hypoxaemia in cirrhosis: fact or fiction? Gut 1998;42:868-74.
38. Martinez GP, Barbera JA, Visa J, Rimola A, Pare JC, Roca J, et al. Hepatopulmonary syndrome in candidates for liver transplantation. J Hepatol 2001;34:651-7.
39. Rodman T, Sobel M, Close HP. Arterial oxygen unsaturation and ventilation-perfusion defect of Laënnecs cirrhosis. N Engl J Med 1960;263:73-7.
40. Eriksson LS, Söderman C, Ericzon BG, Eleborg L, Wahren J, Hedenstierna G. Normalization of ventilation/perfusion relationships after liver transplantation in patients with decompensated cirrhosis: evidence for a hepatopulmonary syndrome. Hepatology 1990;12:1350-7.
41. Hedenstierna G, Söderman C, Eriksson LS, Wahren J. Ventilation-perfusion inequality in patients with non-alcoholic liver cirrhosis. Eur Respir J 1991;4:711-7.
42. Herve P, Lebrec D, Brenot F, Simonneau G, Humbert M, Sitbon O, et al. Pulmonary vascular disorders in portal hypertension. Eur Resp J 1998;11:1153-66.
43. Söderman C, Eriksson LS, Juhlin-Dannfelt A, Lundberg JM, Broman L, Holmgren A. Effect of vasoactive intestinal polypeptide (VIP) on pulmonary ventilation-perfusion relationships and central haemodynamics in healthy subjects. Clin Physiol 1993;13:677-85.
44. Söderman C, Juhlin-Dannfelt A, Lagerstrand L, Eriksson LS. Ventilation-perfusion relationships and central haemodynamics in patients with cirrhosis. Effects of a somatostatin analogue. J Hepatol 1994;21:52-7.
45. Rakela J, Krowka MJ. Cardiovascular and pulmonary complications of liver disease. In: Zakim D, Boyer TD, editors. Hepatology. A textbook of liver disease. Philadelphia: W.B. Saunders; 1996. pp 675-84.
46. Henriksen JH, Bendtsen F, Sørensen TIA, Stadeager C, Ring-Larsen H. Reduced central blood volume in cirrhosis. Gastroenterology 1989;97:1506-13.
47. Møller S, Burchardt H, ∅gard CG, Schiødt F, Lund JO. Pulmonary blood volume and transit time in cirrhosis. Relation to lung function. Liver Int 2006;9:1072-8.
48. Katsuta Y, Honma H, Zhang XJ, Ohsuga M, Komeichi H, Shimizu S, et al. Pulmonary blood transit time and impaired arterial oxygenation in patients with chronic liver disease. J Gastroenterol 2005;40:57-63.
49. Gomez FP, Martinez-Palli G, Barbera JA, Roca J, Navasa M, Rodriguez-Roisin R. Gas exchange mechanism of orthodeoxia in hepatopulmonary syndrome. Hepatology 2004;40:660-6.
50. Abrams GA, Nanda NC, Dubovsky EV, Krowka MJ, Fallon MB. Use of macroaggregated albumin lung perfusion scan to diagnose hepatopulmonary syndrome: a new approach. Gastroenterology 1998;114:305-10.
51. Koksal D, Kacar S, Koksal AS, Tufekcioglu O, Kucukay F, Okten S, et al. Evaluation of intrapulmonary vascular dilatations with high-resolution computed thorax tomography in patients with hepatopulmonary syndrome. J Clin Gastroenterol 2006;40:77-83.
52. Rodriguez-Roisin R, Krowka MJ. Is severe arterial hypoxaemia due to hepatic disease an indication for liver transplantation? A new therapeutic approach. Eur Resp J 1994;7:839-42.
53. Schenk P, Fuhrmann V, Madl C, Funk G, Lehr S, Kandel O, et al. Hepatopulmonary syndrome: prevalence and predictive value of various cut offs for arterial oxygenation and their clinical consequences. Gut 2002;51:853-9.
54. Gaines DI, Fallon MB. Hepatopulmonary syndrome. Liver Int 2004;24:397-401.
55. Deibert P, Allgaier HP, Stefanie L, Mueller C, Olschewski M, Hamm H, et al. Hepatopulmonary syndrome in patients with chronic liver disease: role of pulse oximetry. BMC Gastroenterol 2006;6:15.
56. Fallon MB, Abrams GA, Luo B, Hou ZY, Dai J, Ku DD. The role of endothelial nitric oxide synthase in the pathogenesis of a rat model of hepatopulmonary syndrome. Gastroenterology 1997;113:606-14.
57. Luo B, Tang L, Wang Z, Zhang J, Ling Y, Feng W, et al. Cholangiocyte endothelin 1 and transforming growth factor beta1 production in rat experimental hepatopulmonary syndrome. Gastroenterology 2005;129:682-95.
58. Fallon MB. Mechanisms of pulmonary vascular complications of liver disease: hepatopulmonary syndrome. J Clin Gastroenterol 2005;39:S138-42.
59. Söderman C, Leone A, Furst V, Persson MG. Endogenous nitric oxide in exhaled air from patients with liver cirrhosis. Scand J Gastroenterol 1997;32:591-7.
60. Rolla G, Brussino L, Colagrande P, Dutto L, Polizzi S, Scappaticci E, et al. Exhaled nitric oxide and oxygenation abnormalities in hepatic cirrhosis. Hepatology 1997;26:842-7.
61. Arguedas MR, Drake BB, Kapoor A, Fallon MB. Carboxyhemoglobin levels in cirrhotic patients with and without hepatopulmonary syndrome. Gastroenterology 2005;128:328-33.
62. Krowka MJ. Pulmonary hypertension: diagnostics and therapeutics. Mayo Clin Proc 2000;75:625-30.
63. Abrams GA, Jaffe CC, Hoffer PB, Binder HJ, Fallon MB. Diagnostic utility of contrast echocardiography and lung perfusion scan in patients with hepatopulmonary syndrome. Gastroenterology 1995;109:1283-8.
64. Aller R, Moya JL, Moreira V, Garcia-Lledo A, Sanroman AL, Paino C, et al. Diagnosis and grading of intrapulmonary vascular dilatation in cirrhotic patients with contrast transesophageal echocardiography. J Hepatol 1999;31:1044-52.
65. Karabulut A, Iltumur K, Yalcin K, Toprak N. Hepatopulmonary syndrome and right ventricular diastolic functions: an echocardiographic examination. Echocardiography 2006;23:271-8.
66. Krishnamurthy GT, Krishnamurthy S. Nuclear hepatology. A textbook of hepatobiliary diseases. Berlin: Springer; 2000.
67. Swanson KL, Wiesner RH, Krowka MJ. Natural history of hepatopulmonary syndrome: impact of liver transplantation. Hepatology 2005;41:1122-9.
68. Riegler JL, Lang KA, Johnson SP, Westerman JH. Transjugular intrahepatic portosystemic shunt improves oxygenation in hepatopulmonary syndrome. Gastroenterology 1995;109:978-83.
69. Schwartz JM, Beymer C, Althaus SJ, Larson AM, Zaman A, Glickerman DJ, et al. Cardiopulmonary consequences of transjugular intrahepatic portosystemic shunts: role of increased pulmonary artery pressure. J Clin Gastroenterol 2004;38:590-4.
70. Boyer TD, Haskal ZJ. The role of transjugular intrahepatic portosystemic shunt in the management of portal hypertension. Hepatology 2005;41:386-400.
71. Murray KF, Carithers RL Jr. AASLD practice guidelines: evaluation of the patient for liver transplantation. Hepatology 2005;41:1407-32.
72. Hadengue A, Kamal KB, Lebrec D, Benhamou JP. Pulmonary hypertension complicating portal hypertension: prevalence and relation to splanchnic hemodynamics. Gastroenterology 1991;100:520-8.
73. Krowka MJ. Portopulmonary hypertension and the issue of survival. Liver Transpl 2005;11:1026-7.
74. Kawut SM, Taichman DB, Ahya VN, Kaplan S, Archer-Chicko CL, Kimmel SE, et al. Hemodynamics and survival of patients with portopulmonary hypertension. Liver Transpl 2005;11:1107-11.
75. Katsuta Y, Zhang XJ, Kato Y, Shimizu S, Komeichi K, Ohsuga M, et al. Hemodynamic features and impaired arterial oxygenation in patients with portopulmonary hypertension. Hepatol Res 2005.
76. Battistini B, Dorleansjuste P, Sirois P. Endothelins and the Lung. M S-Med Sci 1992;8:679-87.
77. Luscher TF. Endothelin-systemic arterial and pulmonary effects of a new peptide with potent biologic properties. Am Rev Respir Dis 1992;146:S56-60.
78. Luo B, Liu L, Tang L, Zhang J, Stockard CR, Grizzle WE, et al. Increased pulmonary vascular endothelin B receptor expression and responsiveness to endothelin-1 in cirrhotic and portal hypertensive rats: a potential mechanism in experimental hepatopulmonary syndrome. J Hepatol 2003;38:556-63.
79. Cody RJ, Haas GJ, Binkley PF, Capers Q, Kelly R. Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure. Circulation 1993;87:1064.
80. Barnes PJ. Endothelins and pulmonary diseases. J Appl Physiol 1994;77:1051-9.
81. Kuntzen C, Gulberg V, Gerbes AL. Use of a mixed endothelin receptor antagonist in portopulmonary hypertension: a safe and effective therapy? Gastroenterology 2005;128:164-8.
82. Hoeper MM, Halank M, Marx C, Hoeffken G, Seyfarth HJ, Schauer J, et al. Bosentan therapy for portopulmonary hypertension. Eur Respir J 2005;25:502-8.
83. Krowka MJ, Plevak D. The distinct concepts and implications of hepatopulmonary syndrome and portopulmonary hypertension. Crit Care Med 2005;33:470.
84. Rodriquez-Roisin R, Krowka MJ, Herve P, Fallon MB. Highlights of the ERS Task Force on pulmonary-hepatic vascular disorders (PHD). J Hepatol 2005;42:924-7.
85. Krowka MJ. Hepatopulmonary syndrome and portopulmonary hypertension: implications for liver transplantation. Clin Chest Med 2005;26:587-97, vi.